A Phase I, Multi-center, Open-label, Dose-escalation Study of Oral LCL161 in Adult Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2014
At a glance
- Drugs LCL 161 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 02 Aug 2012 Trial phase changed from II to I and actual patient number changed from 53 to 71 as reported by ClinicalTrials.gov.
- 12 Jul 2012 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
- 07 May 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.